Estrogen receptor expressing (ER+) breast cancer accounts for over two-thirds of all the breast cancer cases, and they are usually sensitive to anti-estrogen agents including tamoxifen and aromatase inhibitors. This evidence concerns the gene ESR1 and breast carcinoma.